Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$1.96 USD
+0.01 (0.51%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.96 0.00 (0.00%) 7:10 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.96 USD
+0.01 (0.51%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.96 0.00 (0.00%) 7:10 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Zacks News
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 0.00% and 12.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Syros Pharmaceuticals, Inc. (SYRS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 58.18% and 58.26%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) Stock Jumps 7.2%: Will It Continue to Soar?
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -12.96% and 78.06%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Top ETF of December & Its Best Stocks
by Sweta Killa
We have highlighted the best ETF of December and its best performing stocks.
Syros (SYRS) in Focus: Stock Moves 7.9% Higher
by Zacks Equity Research
Syros (SYRS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 5.00% and 45.57%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Syros Pharmaceuticals, Inc. (SYRS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for May 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 19th
Syros Pharmaceuticals Inc (SYRS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals Inc (SYRS) delivered earnings and revenue surprises of 13.33% and 38.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Syros Pharmaceuticals, Inc. (SYRS) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 2.13% and -35.53%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can The Uptrend Continue for Syros Pharmaceuticals?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 2.08% and 29.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syros Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
Syros Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -14.63% and 11.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 14.04% and 7.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -4.44% and -42.78%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 12.24% and -71.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals (SYRS) in Focus: Stock Moves 12.7% Higher
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) was a big mover last session, as the company saw its shares nearly 13% on the day amid huge volumes.
Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings?
by Zacks Equity Research
Henry Schein, Inc. (HSIC) is expected to report first-quarter 2017 results on May 2, before the opening bell.
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings?
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN) is scheduled to report third-quarter fiscal 2017 results on May 2, after the closing bell.